Form 4: Ginkgo Bioworks CFO Reports RSU Vesting & Tax Sale

Ginkgo Bioworks Holdings, Inc. CFO Steven P. Coen reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks Holdings, Inc., reported multiple transactions involving the company's Class A Common Stock.
• On October 16, 2025, Mr. Coen acquired a total of 2,547 shares of Class A Common Stock (1,174, 312, and 1,061 shares) through the vesting of Restricted Stock Units (RSUs).
• Following these acquisitions, his direct beneficial ownership of Class A Common Stock increased to 6,677, 6,989, and 8,050 shares respectively after each vesting event.
• On October 17, 2025, Mr. Coen disposed of 1,312 shares of Class A Common Stock at a price of $13.649 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting of restricted stock and/or RSUs, and not a discretionary trade.
• After the sale, Mr. Coen's direct beneficial ownership of Class A Common Stock was 6,738 shares.
• The filing also details the vesting schedules for the underlying RSUs, with various portions vesting on specific dates in 2024, 2025, and continuing in monthly installments.

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary insider transactions related to executive compensation and tax obligations. It does not contain information that would significantly alter the fundamental outlook or sentiment towards the company, hence a neutral score.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued incentive alignment between the CFO and shareholder interests, as a portion of his compensation is tied to company performance.
• The 'sell to cover' transaction is a non-discretionary event, which is a standard practice for executives to manage tax liabilities upon equity vesting, rather than a signal of lack of confidence in the company.

Negatives

• The sale of 1,312 shares, even for tax purposes, results in a reduction of the CFO's direct ownership in the company.

Risks

• While the sale was for tax purposes, any insider sale, regardless of reason, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term negative sentiment.
• Reliance on equity-based compensation means executive wealth is tied to stock performance, which can fluctuate based on market conditions and company-specific news.

Future Outlook

The filing indicates future share issuances to the CFO as per the remaining vesting schedules of the Restricted Stock Units. One RSU grant will continue to vest in 36 equal monthly installments after May 1, 2024, and another in 46 equal monthly installments after May 1, 2024. A third RSU grant has a final 25% vesting scheduled for January 16, 2026.

Management Comments

• The sale of shares by the Reporting Person was to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units.
• Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

This Form 4 filing reflects a routine executive compensation event common across publicly traded companies. The vesting of Restricted Stock Units (RSUs) and subsequent 'sell to cover' transaction for tax purposes is a standard mechanism for executives to realize value from their equity compensation while fulfilling tax liabilities. This practice is widely observed in the biotechnology and technology sectors, where equity compensation forms a significant part of executive pay.

Comparison to Industry Standards

• The 'sell to cover' transaction for tax withholding is a standard and widely accepted practice in executive compensation across various industries, including biotech and tech, and is not indicative of unusual activity compared to global benchmarks.
• Many companies, such as those in the S&P 500, utilize similar equity incentive plans that include RSUs and allow for 'sell to cover' provisions to manage tax obligations upon vesting.

Stakeholder Impact

• Shareholders: A minor, routine dilution effect from the vesting of RSUs, which is part of the company's established compensation plan. The 'sell to cover' transaction is not a discretionary sale and thus does not signal a change in management's confidence.
• Employees: No direct impact on general employees, but reinforces the company's use of equity-based compensation for executives.

Next Steps

• Continued vesting of Restricted Stock Units (RSUs) for Steven P. Coen according to the established schedules, including monthly installments and a final 25% vesting on January 16, 2026.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Sell to Cover, Executive Compensation, Steven P. Coen, CFO